Skip to content
Colin Angle, iRobot co-Founder and CEO, joins Yahoo Finance's The First Trade to discuss how consumers are investing in at-home technology amid COVID-19. Angle also discusses future technology that iRobot is working on....
Details the CEO buys this past week for the following companies: United Parcel Service, B. Riley Financial, OPKO Health and HP Inc Continue reading......
Winnie Sun, Sun Group Wealth Partners, joins Yahoo Finance's The First Trade to discuss where her clients are investing, including technology in the long-term, savings, travel and more. ...
An editor at both the New York Times and Philadelphia Inquirer chose to resign after facing backlash over controversial headlines. Yahoo Finance's Emily McCormick breaks down the details. ...
Arguably the most controversial on the Street, penny stocks are a hot-button issue. Usually, there isn’t a lot of middle-ground with respect to these tickers priced for less than $5 apiece. Dividing market watchers into two distinct groups, both sides present valid arguments laying out the pros and cons.Sure, there is reason enough to be skeptical. Often, a cheap stock is cheap for a reason, with the low share price potentially reflecting an underlying problem with the business, whether it be poor fundamentals or unbeatable headwinds. That said, a bargain price tag isn’t always indicative of a lost cause. For some, better days are on the horizon, and for very little money, investors can control a lot more shares. Therefore, even minor upward movements could result in massive percentage gains, and thus, significant returns.As the nature of these investments makes it difficult to gauge the strength of their long-term growth prospects,...
(Bloomberg) -- Data on Sarepta Therapeutics Inc.’s experimental gene therapy for a rare type of muscular dystrophy showed that patients receiving a higher dose of the medicine saw greater benefits than those receiving a lower dose, delivering another early-stage win for the drug developer.Three patients with limb-girdle muscular dystrophy Type 2E who got the high dose of Sarepta’s SRP-9003 produced greater levels of the protein beta-sarcoglycan. While patients with the progressive and debilitating muscle-wasting disease normally make very little or none of the protein, the three children showed an average protein expression that was 62% of normal, topping 36% seen at the lower dose, when using a standard analysis called Western Blot.“We see a dose-dependent increase in expression and we see good tolerability across these kids in both the first and second cohort,” Chief Executive Doug Ingram said in an interview.All three patients in the early-stage study saw an average reduction...
